HRP20090454T1 - Derivati pirazola kao inhibitori receptorskih tirozin kinaza - Google Patents

Derivati pirazola kao inhibitori receptorskih tirozin kinaza Download PDF

Info

Publication number: HRP20090454T1
Authority: HR; Croatia
Prior art keywords: amino; 6alkyl; substituted; optionally; formula
Prior art date: 2003-11-17

Application number

HR20090454T

Other languages

English (en)

Croatian (hr)

Inventor

Howard Block Michael

Han Yongxin

Anthony Josey John

W. Lee John

Scott David

Wang Bin

Wang Haixia

Wang Tao

Yu Dingwei

Original Assignee

Astrazeneca Ab

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2003-11-17

Filing date

2009-08-21

Publication date

2009-09-30

2009-08-21 Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab

2009-09-30 Publication of HRP20090454T1 publication Critical patent/HRP20090454T1/hr

Links

239000003112 inhibitor Substances 0.000 title 1
150000003217 pyrazoles Chemical class 0.000 title 1
102000027426 receptor tyrosine kinases Human genes 0.000 title 1
108091008598 receptor tyrosine kinases Proteins 0.000 title 1
-1 nitro, cyano, hydroxy, trifluoromethoxy, amino, carboxy, carbamyl Chemical group 0.000 claims abstract 62
125000000623 heterocyclic group Chemical group 0.000 claims abstract 25
229910052757 nitrogen Inorganic materials 0.000 claims abstract 23
OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims abstract 22
150000001875 compounds Chemical class 0.000 claims abstract 21
229910052799 carbon Inorganic materials 0.000 claims abstract 20
125000000217 alkyl group Chemical group 0.000 claims abstract 18
125000004169 (C1-C6) alkyl group Chemical group 0.000 claims abstract 16
125000003917 carbamoyl group Chemical group [H]N([H])C(*)=O 0.000 claims abstract 13
125000005843 halogen group Chemical group 0.000 claims abstract 13
239000001257 hydrogen Substances 0.000 claims abstract 12
229910052739 hydrogen Inorganic materials 0.000 claims abstract 12
125000004433 nitrogen atom Chemical group N* 0.000 claims abstract 12
125000004452 carbocyclyl group Chemical group 0.000 claims abstract 11
GOJUJUVQIVIZAV-UHFFFAOYSA-N 2-amino-4,6-dichloropyrimidine-5-carbaldehyde Chemical group NC1=NC(Cl)=C(C=O)C(Cl)=N1 GOJUJUVQIVIZAV-UHFFFAOYSA-N 0.000 claims abstract 10
125000003545 alkoxy group Chemical group 0.000 claims abstract 7
125000004397 aminosulfonyl group Chemical group NS(=O)(=O)* 0.000 claims abstract 7
125000004454 (C1-C6) alkoxycarbonyl group Chemical group 0.000 claims abstract 6
125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims abstract 6
125000004845 (C1-C6) alkylsulfonylamino group Chemical group 0.000 claims abstract 5
125000000882 C2-C6 alkenyl group Chemical group 0.000 claims abstract 5
125000003601 C2-C6 alkynyl group Chemical group 0.000 claims abstract 5
125000004435 hydrogen atom Chemical class [H]* 0.000 claims abstract 3
150000003839 salts Chemical class 0.000 claims 15
IJGRMHOSHXDMSA-UHFFFAOYSA-N nitrogen Substances N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims 12
125000002619 bicyclic group Chemical group 0.000 claims 10
125000004429 atom Chemical group 0.000 claims 8
125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 8
150000002431 hydrogen Chemical group 0.000 claims 7
238000000034 method Methods 0.000 claims 6
125000000714 pyrimidinyl group Chemical group 0.000 claims 6
229920006395 saturated elastomer Polymers 0.000 claims 6
125000004191 (C1-C6) alkoxy group Chemical group 0.000 claims 5
125000004193 piperazinyl group Chemical group 0.000 claims 5
125000002373 5 membered heterocyclic group Chemical group 0.000 claims 4
125000004070 6 membered heterocyclic group Chemical group 0.000 claims 4
PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 claims 4
206010028980 Neoplasm Diseases 0.000 claims 4
CZPWVGJYEJSRLH-UHFFFAOYSA-N Pyrimidine Chemical compound C1=CN=CN=C1 CZPWVGJYEJSRLH-UHFFFAOYSA-N 0.000 claims 4
239000003814 drug Substances 0.000 claims 4
125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims 4
239000011737 fluorine Substances 0.000 claims 4
229910052731 fluorine Inorganic materials 0.000 claims 4
125000002950 monocyclic group Chemical group 0.000 claims 4
229910052717 sulfur Inorganic materials 0.000 claims 4
125000000954 2-hydroxyethyl group Chemical group [H]C([*])([H])C([H])([H])O[H] 0.000 claims 3
125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 claims 3
201000011510 cancer Diseases 0.000 claims 3
229940079593 drug Drugs 0.000 claims 3
125000002887 hydroxy group Chemical group [H]O* 0.000 claims 3
238000004519 manufacturing process Methods 0.000 claims 3
125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims 3
125000004739 (C1-C6) alkylsulfonyl group Chemical group 0.000 claims 2
125000004008 6 membered carbocyclic group Chemical group 0.000 claims 2
ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical group [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 claims 2
OAKJQQAXSVQMHS-UHFFFAOYSA-N Hydrazine Chemical compound NN OAKJQQAXSVQMHS-UHFFFAOYSA-N 0.000 claims 2
UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 2
206010041067 Small cell lung cancer Diseases 0.000 claims 2
NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 claims 2
QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims 2
125000003236 benzoyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C(*)=O 0.000 claims 2
125000001584 benzyloxycarbonyl group Chemical group C(=O)(OCC1=CC=CC=C1)* 0.000 claims 2
125000002837 carbocyclic group Chemical group 0.000 claims 2
239000000460 chlorine Chemical group 0.000 claims 2
229910052801 chlorine Inorganic materials 0.000 claims 2
125000003754 ethoxycarbonyl group Chemical group C(=O)(OCC)* 0.000 claims 2
125000001153 fluoro group Chemical group F* 0.000 claims 2
201000001441 melanoma Diseases 0.000 claims 2
125000001160 methoxycarbonyl group Chemical group [H]C([H])([H])OC(*)=O 0.000 claims 2
125000004573 morpholin-4-yl group Chemical group N1(CCOCC1)* 0.000 claims 2
QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 claims 2
208000002154 non-small cell lung carcinoma Diseases 0.000 claims 2
229910052760 oxygen Inorganic materials 0.000 claims 2
239000001301 oxygen Substances 0.000 claims 2
125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 2
UYWQUFXKFGHYNT-UHFFFAOYSA-N phenylmethyl ester of formic acid Natural products O=COCC1=CC=CC=C1 UYWQUFXKFGHYNT-UHFFFAOYSA-N 0.000 claims 2
125000003170 phenylsulfonyl group Chemical group C1(=CC=CC=C1)S(=O)(=O)* 0.000 claims 2
125000004076 pyridyl group Chemical group 0.000 claims 2
125000000719 pyrrolidinyl group Chemical group 0.000 claims 2
208000000587 small cell lung carcinoma Diseases 0.000 claims 2
125000001424 substituent group Chemical group 0.000 claims 2
239000011593 sulfur Substances 0.000 claims 2
125000004434 sulfur atom Chemical group 0.000 claims 2
XTQHKBHJIVJGKJ-UHFFFAOYSA-N sulfur monoxide Chemical class S=O XTQHKBHJIVJGKJ-UHFFFAOYSA-N 0.000 claims 2
229910052815 sulfur oxide Inorganic materials 0.000 claims 2
125000000335 thiazolyl group Chemical group 0.000 claims 2
125000001544 thienyl group Chemical group 0.000 claims 2
208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 claims 2
MAYHUFQBMJUHBX-HNNXBMFYSA-N (2r)-2-[[4-[(5-cyclopropyl-1h-pyrazol-3-yl)amino]-5-fluoropyrimidin-2-yl]amino]-2-(4-fluorophenyl)ethanol Chemical compound N([C@@H](CO)C=1C=CC(F)=CC=1)C(N=1)=NC=C(F)C=1NC(=NN1)C=C1C1CC1 MAYHUFQBMJUHBX-HNNXBMFYSA-N 0.000 claims 1
ODABQTDWBANHOR-IBGZPJMESA-N (2r)-2-[[4-[(5-cyclopropyl-1h-pyrazol-3-yl)amino]-7-fluoroquinazolin-2-yl]amino]-2-(4-fluorophenyl)ethanol Chemical compound N([C@@H](CO)C=1C=CC(F)=CC=1)C(N=C1C=C(F)C=CC1=1)=NC=1NC(=NN1)C=C1C1CC1 ODABQTDWBANHOR-IBGZPJMESA-N 0.000 claims 1
CQGHCBOWEXGQAU-AWEZNQCLSA-N (2r)-2-[[5-chloro-4-[(3-propan-2-yloxy-1h-pyrazol-5-yl)amino]pyrimidin-2-yl]amino]-2-(4-fluorophenyl)ethanol Chemical compound N1N=C(OC(C)C)C=C1NC1=NC(N[C@@H](CO)C=2C=CC(F)=CC=2)=NC=C1Cl CQGHCBOWEXGQAU-AWEZNQCLSA-N 0.000 claims 1
FXSOVNSBVDXYOV-HNNXBMFYSA-N (2r)-2-[[5-chloro-4-[(5-cyclopropyl-1h-pyrazol-3-yl)amino]pyrimidin-2-yl]amino]-2-(4-fluorophenyl)ethanol Chemical compound N([C@@H](CO)C=1C=CC(F)=CC=1)C(N=1)=NC=C(Cl)C=1NC(NN=1)=CC=1C1CC1 FXSOVNSBVDXYOV-HNNXBMFYSA-N 0.000 claims 1
SDYJEUJNTJEGGY-HNNXBMFYSA-N (3s)-3-[[5-chloro-4-[(5-cyclopropyl-1h-pyrazol-3-yl)amino]pyrimidin-2-yl]amino]-3-(4-fluorophenyl)-n-methylpropanamide Chemical compound N([C@@H](CC(=O)NC)C=1C=CC(F)=CC=1)C(N=1)=NC=C(Cl)C=1NC(=NN1)C=C1C1CC1 SDYJEUJNTJEGGY-HNNXBMFYSA-N 0.000 claims 1
ILROLYQPRYHHFG-UHFFFAOYSA-N 1-$l^{1}-oxidanylprop-2-en-1-one Chemical group [O]C(=O)C=C ILROLYQPRYHHFG-UHFFFAOYSA-N 0.000 claims 1
125000004066 1-hydroxyethyl group Chemical group [H]OC([H])([*])C([H])([H])[H] 0.000 claims 1
XFGQQCZWCNSYOC-LBPRGKRZSA-N 2-[[5-chloro-2-[[(1s)-1-(4-fluorophenyl)ethyl]amino]-6-[(3-propan-2-yloxy-1h-pyrazol-5-yl)amino]pyrimidin-4-yl]amino]propane-1,3-diol Chemical compound N1C(OC(C)C)=CC(NC=2C(=C(NC(CO)CO)N=C(N[C@@H](C)C=3C=CC(F)=CC=3)N=2)Cl)=N1 XFGQQCZWCNSYOC-LBPRGKRZSA-N 0.000 claims 1
SWQAOASNZJKPPA-INIZCTEOSA-N 2-[[5-chloro-6-[(5-cyclopropyl-1h-pyrazol-3-yl)amino]-2-[[(1r)-1-(4-fluorophenyl)-2-hydroxyethyl]amino]pyrimidin-4-yl]amino]propane-1,3-diol Chemical compound C1([C@H](CO)NC=2N=C(C(=C(NC3=NNC(=C3)C3CC3)N=2)Cl)NC(CO)CO)=CC=C(F)C=C1 SWQAOASNZJKPPA-INIZCTEOSA-N 0.000 claims 1
KJZIVTDADVVLOO-NSHDSACASA-N 2-[[5-chloro-6-[(5-cyclopropyl-1h-pyrazol-3-yl)amino]-2-[[(1s)-1-(4-fluorophenyl)ethyl]amino]pyrimidin-4-yl]amino]propane-1,3-diol Chemical compound N([C@@H](C)C=1C=CC(F)=CC=1)C(N=1)=NC(NC(CO)CO)=C(Cl)C=1NC(NN=1)=CC=1C1CC1 KJZIVTDADVVLOO-NSHDSACASA-N 0.000 claims 1
125000003006 2-dimethylaminoethyl group Chemical group [H]C([H])([H])N(C([H])([H])[H])C([H])([H])C([H])([H])* 0.000 claims 1
125000001054 5 membered carbocyclic group Chemical group 0.000 claims 1
BJULBAQIZYUYFI-JTQLQIEISA-N 5-bromo-4-n-(5-cyclopropyl-1h-pyrazol-3-yl)-2-n-[(1s)-1-(4-fluorophenyl)ethyl]pyrimidine-2,4-diamine Chemical compound N([C@@H](C)C=1C=CC(F)=CC=1)C(N=1)=NC=C(Br)C=1NC(NN=1)=CC=1C1CC1 BJULBAQIZYUYFI-JTQLQIEISA-N 0.000 claims 1
206010006187 Breast cancer Diseases 0.000 claims 1
208000026310 Breast neoplasm Diseases 0.000 claims 1
WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical group [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 claims 1
206010009944 Colon cancer Diseases 0.000 claims 1
208000000461 Esophageal Neoplasms Diseases 0.000 claims 1
208000006168 Ewing Sarcoma Diseases 0.000 claims 1
201000008808 Fibrosarcoma Diseases 0.000 claims 1
201000003741 Gastrointestinal carcinoma Diseases 0.000 claims 1
208000007766 Kaposi sarcoma Diseases 0.000 claims 1
208000008839 Kidney Neoplasms Diseases 0.000 claims 1
206010058467 Lung neoplasm malignant Diseases 0.000 claims 1
206010025323 Lymphomas Diseases 0.000 claims 1
206010029260 Neuroblastoma Diseases 0.000 claims 1
206010030155 Oesophageal carcinoma Diseases 0.000 claims 1
206010033128 Ovarian cancer Diseases 0.000 claims 1
206010061535 Ovarian neoplasm Diseases 0.000 claims 1
206010061902 Pancreatic neoplasm Diseases 0.000 claims 1
206010035226 Plasma cell myeloma Diseases 0.000 claims 1
206010060862 Prostate cancer Diseases 0.000 claims 1
208000000236 Prostatic Neoplasms Diseases 0.000 claims 1
206010038389 Renal cancer Diseases 0.000 claims 1
208000005718 Stomach Neoplasms Diseases 0.000 claims 1
125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 claims 1
125000004202 aminomethyl group Chemical group [H]N([H])C([H])([H])* 0.000 claims 1
230000001028 anti-proliverative effect Effects 0.000 claims 1
GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Chemical group BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 claims 1
229910052794 bromium Inorganic materials 0.000 claims 1
125000004744 butyloxycarbonyl group Chemical group 0.000 claims 1
125000002057 carboxymethyl group Chemical group [H]OC(=O)C([H])([H])[*] 0.000 claims 1
210000003169 central nervous system Anatomy 0.000 claims 1
208000029742 colonic neoplasm Diseases 0.000 claims 1
125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 claims 1
125000004186 cyclopropylmethyl group Chemical group [H]C([H])(*)C1([H])C([H])([H])C1([H])[H] 0.000 claims 1
239000003937 drug carrier Substances 0.000 claims 1
230000000694 effects Effects 0.000 claims 1
201000004101 esophageal cancer Diseases 0.000 claims 1
125000006125 ethylsulfonyl group Chemical group 0.000 claims 1
206010017758 gastric cancer Diseases 0.000 claims 1
201000010536 head and neck cancer Diseases 0.000 claims 1
208000014829 head and neck neoplasm Diseases 0.000 claims 1
125000004029 hydroxymethyl group Chemical group [H]OC([H])([H])* 0.000 claims 1
230000002401 inhibitory effect Effects 0.000 claims 1
201000002313 intestinal cancer Diseases 0.000 claims 1
125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 claims 1
201000010982 kidney cancer Diseases 0.000 claims 1
208000032839 leukemia Diseases 0.000 claims 1
201000005202 lung cancer Diseases 0.000 claims 1
208000020816 lung neoplasm Diseases 0.000 claims 1
208000015486 malignant pancreatic neoplasm Diseases 0.000 claims 1
125000004184 methoxymethyl group Chemical group [H]C([H])([H])OC([H])([H])* 0.000 claims 1
125000004170 methylsulfonyl group Chemical group [H]C([H])([H])S(*)(=O)=O 0.000 claims 1
201000000050 myeloid neoplasm Diseases 0.000 claims 1
125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims 1
201000008968 osteosarcoma Diseases 0.000 claims 1
125000004430 oxygen atom Chemical group O* 0.000 claims 1
201000002528 pancreatic cancer Diseases 0.000 claims 1
208000008443 pancreatic carcinoma Diseases 0.000 claims 1
210000001428 peripheral nervous system Anatomy 0.000 claims 1
239000000546 pharmaceutical excipient Substances 0.000 claims 1
230000002265 prevention Effects 0.000 claims 1
125000002572 propoxy group Chemical group [*]OC([H])([H])C(C([H])([H])[H])([H])[H] 0.000 claims 1
125000006239 protecting group Chemical group 0.000 claims 1
125000002294 quinazolinyl group Chemical group N1=C(N=CC2=CC=CC=C12)* 0.000 claims 1
239000002904 solvent Substances 0.000 claims 1
201000011549 stomach cancer Diseases 0.000 claims 1
125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 claims 1
125000000876 trifluoromethoxy group Chemical group FC(F)(F)O* 0.000 claims 1
125000004890 (C1-C6) alkylamino group Chemical group 0.000 abstract 2

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
- C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D495/04—Ortho-condensed systems

Landscapes

Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Health & Medical Sciences (AREA)
Animal Behavior & Ethology (AREA)
Pharmacology & Pharmacy (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
Medicinal Chemistry (AREA)
General Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Rheumatology (AREA)
Immunology (AREA)
Physical Education & Sports Medicine (AREA)
Urology & Nephrology (AREA)
Orthopedic Medicine & Surgery (AREA)
Pain & Pain Management (AREA)
Oncology (AREA)
Heart & Thoracic Surgery (AREA)
Cardiology (AREA)
Ophthalmology & Optometry (AREA)
Hematology (AREA)
Vascular Medicine (AREA)
Dermatology (AREA)
Epidemiology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Nitrogen Condensed Heterocyclic Rings (AREA)
Plural Heterocyclic Compounds (AREA)
Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)

HR20090454T 2003-11-17 2009-08-21 Derivati pirazola kao inhibitori receptorskih tirozin kinaza HRP20090454T1 (hr)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
US52058103P	2003-11-17	2003-11-17
US55621304P	2004-03-25	2004-03-25
PCT/GB2004/004784 WO2005049033A1 (en)	2003-11-17	2004-11-15	Pyrazole derivatives as inhibitors of receptor tyrosyne kinases

Publications (1)

Publication Number	Publication Date
HRP20090454T1 true HRP20090454T1 (hr)	2009-09-30

Family

ID=34623139

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
HR20090454T HRP20090454T1 (hr)	2003-11-17	2009-08-21	Derivati pirazola kao inhibitori receptorskih tirozin kinaza

Country Status (26)

Country	Link
US (2)	US20070142413A1 (ko)
EP (1)	EP1686999B1 (ko)
JP (2)	JP4942486B2 (ko)
KR (2)	KR101192939B1 (ko)
AR (1)	AR046779A1 (ko)
AT (1)	ATE435017T1 (ko)
AU (1)	AU2004290948B2 (ko)
BR (1)	BRPI0416605A (ko)
CA (1)	CA2545527C (ko)
CY (1)	CY1110498T1 (ko)
DE (1)	DE602004021844D1 (ko)
DK (1)	DK1686999T3 (ko)
ES (1)	ES2328042T3 (ko)
HK (1)	HK1092723A1 (ko)
HR (1)	HRP20090454T1 (ko)
IL (1)	IL175487A (ko)
MY (1)	MY141220A (ko)
NO (1)	NO20062188L (ko)
NZ (1)	NZ547938A (ko)
PL (1)	PL1686999T3 (ko)
PT (1)	PT1686999E (ko)
RU (1)	RU2413727C2 (ko)
SI (1)	SI1686999T1 (ko)
TW (1)	TWI343383B (ko)
UY (1)	UY28623A1 (ko)
WO (1)	WO2005049033A1 (ko)

Families Citing this family (119)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
SE0104140D0 (sv) *	2001-12-07	2001-12-07	Astrazeneca Ab	Novel Compounds
PT1599468E (pt)	2003-01-14	2008-01-14	Arena Pharm Inc	Derivados de arilo e heteroarilo 1,2,3.-trissubstituídos comomoduladores do metabolismo, e profilaxia e tratamento dedesordens relacionadas tais como diabetes e hiperglicemia
TW200530235A (en)	2003-12-24	2005-09-16	Renovis Inc	Bicycloheteroarylamine compounds as ion channel ligands and uses thereof
US7793137B2 (en)	2004-10-07	2010-09-07	Cisco Technology, Inc.	Redundant power and data in a wired data telecommunincations network
EP1812439B2 (en)	2004-10-15	2017-12-06	Takeda Pharmaceutical Company Limited	Kinase inhibitors
JP5208516B2 (ja)	2004-12-30	2013-06-12	エグゼリクシス，インコーポレイテッド	キナーゼモジュレーターとしてのピリミジン誘導体および使用方法
EP2383268B1 (en) *	2005-02-04	2015-09-02	AstraZeneca AB	Pyrazolylaminopyridine derivatives useful as kinase inhibitors
DE602006001515D1 (de)	2005-02-16	2008-07-31	Astrazeneca Ab	Chemische verbindungen
US7297700B2 (en)	2005-03-24	2007-11-20	Renovis, Inc.	Bicycloheteroaryl compounds as P2X7 modulators and uses thereof
JP2008540335A (ja) *	2005-04-27	2008-11-20	アストラゼネカ・アクチエボラーグ	ピラゾリル・ピリミジン誘導体の疼痛治療における使用
WO2006119504A2 (en)	2005-05-04	2006-11-09	Renovis, Inc.	Fused heterocyclic compounds, and compositions and uses thereof
MX2007014328A (es) *	2005-05-16	2008-02-12	Astrazeneca Ab	Compuestos quimicos.
US8119655B2 (en)	2005-10-07	2012-02-21	Takeda Pharmaceutical Company Limited	Kinase inhibitors
CN101346371B (zh) *	2005-10-28	2012-11-14	阿斯利康(瑞典)有限公司	癌症治疗中用作酪氨酸激酶抑制剂的4-(3-氨基吡唑)嘧啶衍生物
TW200800963A (en) *	2005-10-28	2008-01-01	Astrazeneca Ab	Chemical compounds
TW200736250A (en) *	2005-11-03	2007-10-01	Vertex Pharma	Aminopyrimidines useful as kinase inhibitors
US7514435B2 (en) *	2005-11-18	2009-04-07	Bristol-Myers Squibb Company	Pyrrolotriazine kinase inhibitors
EA019504B1 (ru)	2005-12-13	2014-04-30	Инсайт Корпорейшн	ГЕТЕРОАРИЛЗАМЕЩЕННЫЕ ПИРРОЛО[2,3-b]ПИРИДИНЫ И ПИРРОЛО[2,3-b]ПИРИМИДИНЫ В КАЧЕСТВЕ ИНГИБИТОРОВ ЯНУС-КИНАЗЫ
JP2009521479A (ja) *	2005-12-21	2009-06-04	アボット・ラボラトリーズ	抗ウイルス化合物
WO2007081517A2 (en)	2005-12-21	2007-07-19	Abbott Laboratories	Anti-viral compounds
EP1847543A1 (de)	2006-04-19	2007-10-24	Boehringer Ingelheim Pharma GmbH & Co. KG	Dihydrothienopyrimidine zur Behandlung von entzündlichen Erkrankungen
EP2060575A1 (de) *	2006-04-19	2009-05-20	Boehringer Ingelheim International GmbH	Dihydrothienopyrimidine zur Behandlung von entzündlichen Erkrankungen
CA2649043C (en)	2006-04-19	2013-09-17	Astellas Pharma Inc.	Azolecarboxamide derivative
KR20090024270A (ko) *	2006-06-30	2009-03-06	아스트라제네카 아베	암 치료에 유용한 피리미딘 유도체
US8222256B2 (en)	2006-07-05	2012-07-17	Exelixis, Inc.	Methods of using IGFIR and ABL kinase modulators
EP2469283B1 (en) *	2006-09-08	2014-01-15	The Chancellor, Masters and Scholars of the University of Oxford	Clinical diagnosis of hepatic fibrosis using human serum APOL1 as biomarker
JP2010505962A (ja)	2006-10-09	2010-02-25	武田薬品工業株式会社	キナーゼ阻害剤
TW200823196A (en) *	2006-11-01	2008-06-01	Astrazeneca Ab	New use
US8236950B2 (en)	2006-12-20	2012-08-07	Abbott Laboratories	Anti-viral compounds
US9187485B2 (en)	2007-02-02	2015-11-17	Baylor College Of Medicine	Methods and compositions for the treatment of cancer and related hyperproliferative disorders
JP2010524911A (ja) *	2007-04-18	2010-07-22	アストラゼネカアクチボラグ	５−アミノピラゾール−３−イル−３Ｈ−イミダゾ［４，５−ｂ］ピリジン誘導体と癌の治療のためのその使用
UY31048A1 (es) *	2007-04-25	2008-11-28	Astrazeneca Ab	Nuevos compuestos de pirimidina y usos de los mismos
UA99459C2 (en) *	2007-05-04	2012-08-27	Астразенека Аб	9-(pyrazol-3-yl)- 9h-purine-2-amine and 3-(pyraz0l-3-yl)-3h-imidazo[4,5-b]pyridin-5-amine derivatives and their use for the treatment of cancer
AU2008266183B2 (en)	2007-06-13	2013-09-12	Incyte Holdings Corporation	Salts of the Janus kinase inhibitor (R)-3-(4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl)-3-cyclopentylpropanenitrile
WO2009013545A2 (en) *	2007-07-26	2009-01-29	Astrazeneca Ab	Chemical compounds
WO2009019518A1 (en) *	2007-08-09	2009-02-12	Astrazeneca Ab	Pyrimidine compounds having a fgfr inhibitory effect
JP5563466B2 (ja)	2007-10-19	2014-07-30	ベーリンガーインゲルハイムインターナショナルゲゼルシャフトミットベシュレンクテルハフツング	新規ピペラジノ−ジヒドロチエノピリミジン誘導体
ES2524910T3 (es)	2007-10-19	2014-12-15	Boehringer Ingelheim International Gmbh	Piperidino-dihidrotienopirimidinas sustituidas
KR20100075930A (ko)	2007-10-19	2010-07-05	베링거 인겔하임 인터내셔날 게엠베하	헤테로사이클-치환된 피페라지노-디하이드로티에노피리미딘
AU2008314922B2 (en)	2007-10-24	2013-08-29	Astellas Pharma Inc.	Azolecarboxamide compound or salt thereof
WO2009056886A1 (en) *	2007-11-01	2009-05-07	Astrazeneca Ab	Pyrimidine derivatives and their use as modulators of fgfr activity
CN101910152B (zh)	2007-11-16	2014-08-06	因塞特公司	作为janus激酶抑制剂的4-吡唑基-n-芳基嘧啶-2-胺和4-吡唑基-n-杂芳基嘧啶-2-胺
WO2009088054A1 (ja)	2008-01-11	2009-07-16	Astellas Pharma Inc.	精巣の疼痛又は不快感行動及び頻尿併発モデル動物
EP2288602A1 (en) *	2008-06-11	2011-03-02	AstraZeneca AB	Tricyclic 2,4-diamin0-l,3,5-triazine derivatives useful for the treatment of cancer and myeloproliferative disorders
ES2464461T3 (es)	2008-09-22	2014-06-02	Array Biopharma, Inc.	Compuestos de imidazo[1,2B]piridazina sustituidos como inhibidores de la TRK cinasa
AU2009299599A1 (en) *	2008-09-30	2010-04-08	Astrazeneca Ab	Heterocyclic JAK kinase inhibitors
KR101853026B1 (ko)	2008-10-22	2018-04-27	어레이 바이오파마 인크.	ＴＲＫ 키나아제 억제제로서 치환된 피라졸로［１,５ａ］ 피리미딘 화합물
EP2210879A1 (de) *	2008-12-30	2010-07-28	Bayer CropScience AG	Pyrimidinderivate und ihre Verwendung zur Bekämpfung unerwünschten Pflanzenwachstums
WO2010114894A1 (en)	2009-03-31	2010-10-07	Arqule, Inc.	Substituted heterocyclic compounds
ES2527455T3 (es) *	2009-05-14	2015-01-23	The Chancellor, Masters And Scholars Of The University Of Oxford	Diagnóstico clínico de fibrosis/cirrosis hepática usando biomarcadores de proteínas plasmáticas humanas poco abundantes
MX2011012262A (es)	2009-05-22	2012-01-25	Incyte Corp	3-[4-(7h-pirrolo[2,3-d]pirimidin-4-il)-1h-pirazol-1-il] octano-o heptano-nitrilo como inhibidores de cinasas janus (jak).
JP5775070B2 (ja)	2009-05-22	2015-09-09	インサイト・コーポレイションＩｎｃｙｔｅＣｏｒｐｏｒａｔｉｏｎ	ヤヌスキナーゼ阻害剤としてのピラゾール−４−イル−ピロロ［２，３−ｄ］ピリミジンおよびピロール−３−イル−ピロロ［２，３−ｄ］ピリミジンのＮ−（ヘテロ）アリール−ピロリジン誘導体
AR077468A1 (es)	2009-07-09	2011-08-31	Array Biopharma Inc	Compuestos de pirazolo (1,5 -a) pirimidina sustituidos como inhibidores de trk- quinasa
US8933227B2 (en)	2009-08-14	2015-01-13	Boehringer Ingelheim International Gmbh	Selective synthesis of functionalized pyrimidines
US8729265B2 (en)	2009-08-14	2014-05-20	Boehringer Ingelheim International Gmbh	Regioselective preparation of 2-amino-5-trifluoromethylpyrimidine derivatives
TW201113285A (en)	2009-09-01	2011-04-16	Incyte Corp	Heterocyclic derivatives of pyrazol-4-yl-pyrrolo[2,3-d]pyrimidines as janus kinase inhibitors
DK3354652T3 (da)	2010-03-10	2020-05-18	Incyte Holdings Corp	Piperidin-4-yl azetidinderivativer som jak1-inhibitorer
MY191934A (en)	2010-05-20	2022-07-19	Array Biopharma Inc	Macrocyclic compounds as trk kinase inhibitors
DK2574168T3 (en)	2010-05-21	2016-05-09	Incyte Holdings Corp	Topical formulation to a jak inhibitor
DE102010025663A1 (de) *	2010-06-30	2012-01-05	Karl-Heinz Glüsenkamp	Neue beta-Aminoaldehyd-Derivate, Verfahren zu ihrer Herstellung und ihre chemische Verwendung als reaktive Intermediate
BR112013008100A2 (pt)	2010-09-22	2016-08-09	Arena Pharm Inc	"moduladores do receptor de gpr19 e o tratamento de distúrbios relacionados a eles."
JP5917545B2 (ja)	2010-11-19	2016-05-18	インサイト・ホールディングス・コーポレイションＩｎｃｙｔｅＨｏｌｄｉｎｇｓＣｏｒｐｏｒａｔｉｏｎ	Ｊａｋ阻害剤としてのシクロブチル置換ピロロピリジンおよびピロロピリミジン誘導体
WO2012068440A1 (en)	2010-11-19	2012-05-24	Incyte Corporation	Heterocyclic-substituted pyrrolopyridines and pyrrolopyrimidines as jak inhibitors
PT2712358T (pt) *	2011-05-13	2017-02-20	Array Biopharma Inc	Compostos de pirrolidinil ureia, pirrolidinil tioureia e pirrolidinil guanida como inibidores de trka quinase
US8691807B2 (en)	2011-06-20	2014-04-08	Incyte Corporation	Azetidinyl phenyl, pyridyl or pyrazinyl carboxamide derivatives as JAK inhibitors
TW201313721A (zh)	2011-08-18	2013-04-01	Incyte Corp	作為ｊａｋ抑制劑之環己基氮雜環丁烷衍生物
US9802954B2 (en)	2011-08-24	2017-10-31	Boehringer Ingelheim International Gmbh	Piperidino-dihydrothienopyrimidine sulfoxides and their use for treating COPD and asthma
US20130059866A1 (en)	2011-08-24	2013-03-07	Boehringer Ingelheim International Gmbh	Novel piperidino-dihydrothienopyrimidine sulfoxides and their use for treating copd and asthma
RU2014109897A (ru) *	2011-08-25	2015-09-27	Ф.Хоффманн-Ля Рош Аг	Ингибиторы серин/треонин киназы рак1
UA111854C2 (uk)	2011-09-07	2016-06-24	Інсайт Холдінгс Корпорейшн	Способи і проміжні сполуки для отримання інгібіторів jak
BR112014015549A8 (pt) *	2011-12-22	2017-07-04	Hoffmann La Roche	composto, método de inibição da atividade pak1, método para o tratamento, processo, composição, utilização de um composto e invenção
US8916555B2 (en)	2012-03-16	2014-12-23	Axikin Pharmaceuticals, Inc.	3,5-diaminopyrazole kinase inhibitors
AR091079A1 (es)	2012-05-18	2014-12-30	Incyte Corp	Derivados de pirrolopirimidina y pirrolopiridina sustituida con piperidinilciclobutilo como inhibidores de jak
TWI585088B (zh)	2012-06-04	2017-06-01	第一三共股份有限公司	作爲激酶抑制劑之咪唑并［１，２－ｂ］嗒衍生物
JP2015537030A (ja)	2012-11-15	2015-12-24	インサイト・コーポレイションＩｎｃｙｔｅＣｏｒｐｏｒａｔｉｏｎ	ルキソリチニブの徐放性投薬形態
CN103012428A (zh) *	2013-01-08	2013-04-03	中国药科大学	4-(五元杂环并嘧啶/吡啶取代)氨基-1H-3-吡唑甲酰胺类CDK/Aurora双重抑制剂及其用途
KR102366356B1 (ko)	2013-03-06	2022-02-23	인사이트 홀딩스 코포레이션	Jak 저해제를 제조하기 위한 방법 및 중간생성물
JP6334700B2 (ja)	2013-08-07	2018-05-30	インサイト・コーポレイションＩｎｃｙｔｅＣｏｒｐｏｒａｔｉｏｎ	Ｊａｋ１阻害剤のための徐放性剤形
NZ631142A (en)	2013-09-18	2016-03-31	Axikin Pharmaceuticals Inc	Pharmaceutically acceptable salts of 3,5-diaminopyrazole kinase inhibitors
US9498467B2 (en)	2014-05-30	2016-11-22	Incyte Corporation	Treatment of chronic neutrophilic leukemia (CNL) and atypical chronic myeloid leukemia (aCML) by inhibitors of JAK1
FI3699181T3 (fi)	2014-11-16	2023-03-28	Array Biopharma Inc	Kiteinen muoto (s)-n-(5-((r)-2-(2,5-diluorifenyyli)-pyrrolidin-1-yyli)-pyratsolo[1,5-a]pyrimidin-3-yyli)-3-hydroksipyrrolidiini-1-karboksamidivetyysulfaatista
MY191736A (en)	2014-12-23	2022-07-13	Axikin Pharmaceuticals Inc	3,5-diaminopyrazole kinase inhibitors
AU2016205361C1 (en)	2015-01-06	2021-04-08	Arena Pharmaceuticals, Inc.	Methods of treating conditions related to the S1P1 receptor
PE20180329A1 (es)	2015-06-01	2018-02-13	Loxo Oncology Inc	Metodos para diagnosticar y tratar el cancer
CN108349891B (zh)	2015-06-22	2022-04-05	艾尼纳制药公司	用于s1p1受体相关病症的化合物的结晶l-精氨酸盐
KR20180041135A (ko)	2015-07-16	2018-04-23	어레이 바이오파마 인크.	Ret 키나아제 억제제로서 치환된 피라졸로[1,5-a]피리딘 화합물
CA3003153A1 (en)	2015-10-26	2017-05-04	Loxo Oncology, Inc.	Point mutations in trk inhibitor-resistant cancer and methods relating to the same
US10045991B2 (en)	2016-04-04	2018-08-14	Loxo Oncology, Inc.	Methods of treating pediatric cancers
FI3439663T3 (fi)	2016-04-04	2024-08-28	Loxo Oncology Inc	Menetelmiä lasten syöpien hoitamiseksi
CA3019671C (en)	2016-04-04	2024-02-20	Loxo Oncology, Inc.	Liquid formulations of (s)-n-(5-((r)-2-(2,5-difluorophenyl)-pyrrolidin-1-yl)-pyrazolo[1,5-a]pyrimidin-3-yl)-3-hydroxypyrrolidine-1-carboxamide
RS61463B1 (sr)	2016-05-18	2021-03-31	Loxo Oncology Inc	Priprema (s)-n-(5-((r)-2-(2,5-difluorofenil)pirolidin-1-il)pirazolo[1,5-a]pirimidin-3-il) -3-hidroksipirolidin-1-karboksamida
AU2017296338A1 (en)	2016-07-14	2019-01-03	Pfizer Inc.	Novel pyrimidine carboxamides as inhibitors of vanin-1 enzyme
JOP20190077A1 (ar)	2016-10-10	2019-04-09	Array Biopharma Inc	مركبات بيرازولو [1، 5-a]بيريدين بها استبدال كمثبطات كيناز ret
TWI704148B (zh)	2016-10-10	2020-09-11	美商亞雷生物製藥股份有限公司	作為ｒｅｔ激酶抑制劑之經取代吡唑并[1,5-a]吡啶化合物
JOP20190092A1 (ar)	2016-10-26	2019-04-25	Array Biopharma Inc	عملية لتحضير مركبات بيرازولو[1، 5-a]بيريميدين وأملاح منها
WO2018136663A1 (en)	2017-01-18	2018-07-26	Array Biopharma, Inc.	Ret inhibitors
US11168090B2 (en)	2017-01-18	2021-11-09	Array Biopharma Inc.	Substituted pyrazolo[1,5-a]pyrazines as RET kinase inhibitors
AU2018220521A1 (en)	2017-02-16	2019-09-05	Arena Pharmaceuticals, Inc.	Compounds and methods for treatment of primary biliary cholangitis
JOP20190213A1 (ar)	2017-03-16	2019-09-16	Array Biopharma Inc	مركبات حلقية ضخمة كمثبطات لكيناز ros1
TW202410896A (zh)	2017-10-10	2024-03-16	美商絡速藥業公司	6-(2-羥基-2-甲基丙氧基)-4-(6-(6-((6-甲氧基吡啶-3-基)甲基)-3,6-二氮雜雙環[3.1.1]庚-3-基)吡啶-3-基)吡唑并[1,5-a]吡啶-3-甲腈之調配物
TWI791053B (zh)	2017-10-10	2023-02-01	美商亞雷生物製藥股份有限公司	6-(2-羥基-2-甲基丙氧基)-4-(6-(6-((6-甲氧基吡啶-3-基)甲基)-3,6-二氮雜雙環[3.1.1]庚-3-基)吡啶-3-基)吡唑并[1,5-a]吡啶-3-甲腈之結晶形式及其醫藥組合物
US20190247398A1 (en)	2017-10-26	2019-08-15	Array Biopharma Inc.	Formulations of a macrocyclic trk kinase inhibitor
US10596161B2 (en)	2017-12-08	2020-03-24	Incyte Corporation	Low dose combination therapy for treatment of myeloproliferative neoplasms
WO2019143991A1 (en)	2018-01-18	2019-07-25	Array Biopharma Inc.	SUBSTITUTED PYRAZOLO[3,4-d]PYRIMIDINE COMPOUNDS AS RET KINASE INHIBITORS
WO2019143977A1 (en)	2018-01-18	2019-07-25	Array Biopharma Inc.	Substituted pyrrolo[2,3-d]pyrimidines compounds as ret kinase inhibitors
EP3740486A1 (en)	2018-01-18	2020-11-25	Array Biopharma, Inc.	Substituted pyrazolyl[4,3-c]pyridinecompounds as ret kinase inhibitors
MA51771B1 (fr)	2018-01-30	2022-03-31	Incyte Corp	Procédés de préparation de (1-(3-fluoro-2-(trifluorométhyl)isonicotinyl)pipéridine-4-one)
EP3773725A1 (en)	2018-03-29	2021-02-17	Loxo Oncology Inc.	Treatment of trk-associated cancers
ES2980497T3 (es)	2018-03-30	2024-10-01	Incyte Corp	Tratamiento de la hidradenitis supurativa mediante inhibidores de JAK
US12109193B2 (en)	2018-07-31	2024-10-08	Loxo Oncology Inc.	Spray-dried dispersions, formulations, and polymorphs of (s)-5-amino-3-(4-((5-fluoro-2-methoxybenzamido)methyl)phenyl)-1-(1,1,1-trifluoropropan-2-yl)-1H-pyrazole-4-carboxamide
WO2020055672A1 (en)	2018-09-10	2020-03-19	Array Biopharma Inc.	Fused heterocyclic compounds as ret kinase inhibitors
CN113490666A (zh)	2018-12-19	2021-10-08	奥瑞生物药品公司	作为fgfr酪氨酸激酶的抑制剂的取代的吡唑并[1,5-a]吡啶化合物
CN113474337A (zh)	2018-12-19	2021-10-01	奥瑞生物药品公司	作为fgfr抑制剂用于治疗癌症的7-((3，5-二甲氧基苯基)氨基)喹喔啉衍生物
AU2020242287A1 (en)	2019-03-21	2021-09-02	INSERM (Institut National de la Santé et de la Recherche Médicale)	A Dbait molecule in combination with kinase inhibitor for the treatment of cancer
CN114761006A (zh)	2019-11-08	2022-07-15	Inserm(法国国家健康医学研究院)	对激酶抑制剂产生耐药性的癌症的治疗方法
WO2021148581A1 (en)	2020-01-22	2021-07-29	Onxeo	Novel dbait molecule and its use
US11833155B2 (en)	2020-06-03	2023-12-05	Incyte Corporation	Combination therapy for treatment of myeloproliferative neoplasms
WO2022101343A1 (de)	2020-11-16	2022-05-19	Credoxys GmbH	Cer-ethylendiaminketonartige - und cer-salenartige-komplexe und deren verwendung in der organischen elektronik
EP4313975A1 (en) *	2021-03-24	2024-02-07	Athos Therapeutics, Inc.	Small molecules for the treatment of kinase-related diseases

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US20030004174A9 (en) *	2000-02-17	2003-01-02	Armistead David M.	Kinase inhibitors
SE0104140D0 (sv) *	2001-12-07	2001-12-07	Astrazeneca Ab	Novel Compounds

2004
- 2004-11-12 MY MYPI20044727A patent/MY141220A/en unknown
- 2004-11-15 JP JP2006540576A patent/JP4942486B2/ja not_active Expired - Fee Related
- 2004-11-15 KR KR1020067011985A patent/KR101192939B1/ko not_active IP Right Cessation
- 2004-11-15 DK DK04798505T patent/DK1686999T3/da active
- 2004-11-15 PL PL04798505T patent/PL1686999T3/pl unknown
- 2004-11-15 SI SI200431205T patent/SI1686999T1/sl unknown
- 2004-11-15 WO PCT/GB2004/004784 patent/WO2005049033A1/en active Application Filing
- 2004-11-15 ES ES04798505T patent/ES2328042T3/es not_active Expired - Lifetime
- 2004-11-15 KR KR1020127017241A patent/KR20120094084A/ko not_active Application Discontinuation
- 2004-11-15 AT AT04798505T patent/ATE435017T1/de active
- 2004-11-15 RU RU2006121337/04A patent/RU2413727C2/ru not_active IP Right Cessation
- 2004-11-15 DE DE602004021844T patent/DE602004021844D1/de not_active Expired - Lifetime
- 2004-11-15 AU AU2004290948A patent/AU2004290948B2/en not_active Ceased
- 2004-11-15 CA CA2545527A patent/CA2545527C/en not_active Expired - Fee Related
- 2004-11-15 BR BRPI0416605-1A patent/BRPI0416605A/pt not_active IP Right Cessation
- 2004-11-15 US US10/595,807 patent/US20070142413A1/en not_active Abandoned
- 2004-11-15 NZ NZ547938A patent/NZ547938A/en not_active IP Right Cessation
- 2004-11-15 EP EP04798505A patent/EP1686999B1/en not_active Expired - Lifetime
- 2004-11-15 PT PT04798505T patent/PT1686999E/pt unknown
- 2004-11-17 AR ARP040104237A patent/AR046779A1/es not_active Application Discontinuation
- 2004-11-17 UY UY28623A patent/UY28623A1/es not_active Application Discontinuation
- 2004-11-17 TW TW093135262A patent/TWI343383B/zh not_active IP Right Cessation
2006
- 2006-05-08 IL IL175487A patent/IL175487A/en not_active IP Right Cessation
- 2006-05-15 NO NO20062188A patent/NO20062188L/no not_active Application Discontinuation
- 2006-12-11 HK HK06113587.6A patent/HK1092723A1/xx not_active IP Right Cessation
2009
- 2009-08-21 HR HR20090454T patent/HRP20090454T1/hr unknown
- 2009-09-16 CY CY20091100953T patent/CY1110498T1/el unknown
2010
- 2010-02-25 US US12/712,659 patent/US20100152219A1/en not_active Abandoned
2011
- 2011-11-07 JP JP2011243454A patent/JP2012082198A/ja not_active Withdrawn

Also Published As

Publication number	Publication date
EP1686999B1 (en)	2009-07-01
RU2006121337A (ru)	2008-01-10
CA2545527C (en)	2010-11-02
SI1686999T1 (sl)	2009-10-31
MY141220A (en)	2010-03-31
KR101192939B1 (ko)	2012-10-18
BRPI0416605A (pt)	2007-01-30
JP4942486B2 (ja)	2012-05-30
ATE435017T1 (de)	2009-07-15
US20070142413A1 (en)	2007-06-21
CY1110498T1 (el)	2015-04-29
AR046779A1 (es)	2005-12-21
UY28623A1 (es)	2005-06-30
KR20060126660A (ko)	2006-12-08
EP1686999A1 (en)	2006-08-09
JP2012082198A (ja)	2012-04-26
JP2007511589A (ja)	2007-05-10
IL175487A (en)	2013-04-30
CA2545527A1 (en)	2005-06-02
TW200526639A (en)	2005-08-16
RU2413727C2 (ru)	2011-03-10
TWI343383B (en)	2011-06-11
DE602004021844D1 (de)	2009-08-13
NO20062188L (no)	2006-07-27
US20100152219A1 (en)	2010-06-17
KR20120094084A (ko)	2012-08-23
AU2004290948B2 (en)	2009-04-09
PL1686999T3 (pl)	2009-11-30
PT1686999E (pt)	2009-08-26
DK1686999T3 (da)	2009-10-05
WO2005049033A1 (en)	2005-06-02
NZ547938A (en)	2010-01-29
AU2004290948A1 (en)	2005-06-02
HK1092723A1 (en)	2007-02-16
IL175487A0 (en)	2006-09-05
ES2328042T3 (es)	2009-11-06

Publication	Publication Date	Title
HRP20090454T1 (hr)	2009-09-30	Derivati pirazola kao inhibitori receptorskih tirozin kinaza
RU2405780C2 (ru)	2010-12-10	Химические соединения
ES2586588T3 (es)	2016-10-17	Derivados tricíclicos, procedimiento para su preparación y su uso como inhibidores de quinasa
US9896455B2 (en)	2018-02-20	Tricyclic compounds having cytostatic and/or cytotoxic activity and methods of use thereof
AU686334B2 (en)	1998-02-05	Bicyclic compounds capable of inhibiting tyrosine kinases of the epidermal growth factor receptor family
ES2527176T3 (es)	2015-01-21	Compuestos y composiciones como inhibidores de proteína quinasa
ES2797252T3 (es)	2020-12-01	Dihidronaftiridinas y compuestos relacionados útiles como inhibidores de quinasas para el tratamiento de enfermedades proliferativas
AU2013213260B2 (en)	2016-02-18	Imidazopyrrolidinone compounds
CN103930425B (zh)	2016-04-27	蝶啶酮衍生物及其作为egfr、blk、flt3抑制剂的应用
AU2010286569B2 (en)	2013-10-10	Compounds and compositions as protein kinase inhibitors
HRP20171748T1 (hr)	2017-12-29	6-amino kinazolina ili 3-cijano derivati kinolina, postupci priprave i njihova farmaceutska uporaba
ES2639064T3 (es)	2017-10-25	Derivados de 3,4-dihidropirrolo[1,2-a]pirazin-1(2h)-ona sustituidos como inhibidores de cinasa
RU2019120986A (ru)	2021-02-12	Фармацевтическая комбинация, содержащая ингибитор alk и ингибитор shp2
ZA200209412B (en)	2004-02-19	Substituted quinazoline derivatives and their use as inhibitors.
JP2005503345A5 (ko)	2005-12-22
ES2389673T3 (es)	2012-10-30	Derivados de pirrolopirimidina sustituidos, procedimiento para su preparación y su uso como inhibidores de quinasas
AR087336A1 (es)	2014-03-19	Compuestos de 2-(2,4,5-anilino sustituido)pirimidina
PT1797099E (pt)	2010-11-18	Compostos de piperidinilamino-tieno[2,3-d]pirimidina
PE20051061A1 (es)	2005-12-12	5,7-DIAMINOPIRAZOLO[4,3-d] PIRIMIDINAS
IS2807B (is)	2012-09-15	Kínasólínafleiður sem æðamyndunarhindrar og milliefni fyrir þær
HRP20100477T1 (hr)	2010-10-31	Kemijski spojevi
JP2005508336A5 (ko)	2006-01-12
ATE370138T1 (de)	2007-09-15	Neue imidazopyridine und ihre verwendung
SI9600184A (en)	1997-04-30	Heterocyclic ring-fused pyrimidine derivatives
EA016301B1 (ru)	2012-04-30	Пирролопиримидины и их применение